The Gap Between Practice and Guidelines in the Choice of First-line Disease Modifying Antirheumatic Drug in Early Rheumatoid Arthritis: Results from the ESPOIR Cohort

REFERENCES

1. 1.↵
   1. Grimshaw JM,
   2. Russell IT

   . Effect of clinical guidelines on medical practice: a systematic review of rigorous evaluations. Lancet 1993;342:1317–22.

   OpenUrlCrossRefPubMed
2. 2.
   1. Kulkarni K,
   2. Castle G,
   3. Gregory R,
   4. et al

   . Nutrition practice guidelines for type 1 diabetes mellitus positively affect dietitian practices and patient outcomes. The Diabetes Care and Education Dietetic Practice Group. J Am Dietetic Assoc 1998;98:62–70.

   OpenUrlCrossRefPubMed
3. 3.
   1. Debnath D,
   2. Dielehner N,
   3. Gunning KA

   . Guidelines, compliance, and effectiveness: a 12 months’ audit in an acute district general healthcare trust on the two week rule for suspected colorectal cancer. Postgrad Med J 2002;78:748–51.

   OpenUrlAbstract/FREE Full Text
4. 4.
   1. Hebert-Croteau N,
   2. Brisson J,
   3. Latreille J,
   4. Rivard M,
   5. Abdelaziz N,
   6. Martin G

   . Compliance with consensus recommendations for systemic therapy is associated with improved survival of women with node-negative breast cancer. J Clin Oncol 2004;22:3685–93.

   OpenUrlAbstract/FREE Full Text
5. 5.
   1. Vikman S,
   2. Airaksinen KE,
   3. Tierala I,
   4. et al

   . Improved adherence to practice guidelines yields better outcome in high-risk patients with acute coronary syndrome without ST elevation: findings from nationwide FINACS studies. J Intern Med 2004;256:316–23.

   OpenUrlCrossRefPubMed
6. 6.↵
   1. Nieuwlaat R,
   2. Olsson SB,
   3. Lip GY,
   4. et al

   . Guideline-adherent antithrombotic treatment is associated with improved outcomes compared with undertreatment in high-risk patients with atrial fibrillation. The Euro Heart Survey on Atrial Fibrillation. Am Heart J 2007;153:1006–12.

   OpenUrlCrossRefPubMed
7. 7.↵
   1. Rogers AM,
   2. Ramanath VS,
   3. Grzybowski M,
   4. et al

   . The association between guideline-based treatment instructions at the point of discharge and lower 1-year mortality in Medicare patients after acute myocardial infarction: the American College of Cardiology’s Guidelines Applied in Practice (GAP) initiative in Michigan. Am Heart J 2007;154:461–9.

   OpenUrlCrossRefPubMed
8. 8.↵
   1. Kosecoff J,
   2. Kanouse DE,
   3. Rogers WH,
   4. McCloskey L,
   5. Winslow CM,
   6. Brook RH

   . Effects of the National Institutes of Health Consensus Development Program on physician practice. JAMA 1987;258:2708–13.

   OpenUrlCrossRefPubMed
9. 9.↵
   1. Cabana MD,
   2. Rand CS,
   3. Powe NR,
   4. et al

   . Why don’t physicians follow clinical practice guidelines? A framework for improvement. JAMA 1999;282:1458–65.

   OpenUrlCrossRefPubMed
10. 10.↵
    1. Tunis SR,
    2. Hayward RS,
    3. Wilson MC,
    4. et al

    . Internists’ attitudes about clinical practice guidelines. Ann Intern Med 1994;120:956–63.

    OpenUrlCrossRefPubMed
11. 11.↵
    1. Stange KC,
    2. Kelly R,
    3. Chao J,
    4. et al

    . Physician agreement with US Preventive Services Task Force recommendations. J Fam Pract 1992;34:409–16.

    OpenUrlPubMed
12. 12.↵
    1. Grilli R,
    2. Lomas J

    . Evaluating the message: the relationship between compliance rate and the subject of a practice guideline. Med Care 1994;32:202–13.

    OpenUrlCrossRefPubMed
13. 13.↵
    1. Durieux P,
    2. Ravaud P,
    3. Dosquet P,
    4. Durocher A

    . Effectiveness of clinical guideline implementation strategies: systematic review of systematic reviews. [French] Gastroenterol Clin Biol 2000;24:1018–25.

    OpenUrl
14. 14.↵
    1. Saillour-Glenisson F,
    2. Michel P

    . Individual and collective facilitators of and barriers to the use of clinical practice guidelines by physicians: a literature review. Rev Epidemiol Sante Publique 2003;51:65–80.

    OpenUrlPubMed
15. 15.↵
    1. O’Dell JR

    . How is it best to treat early rheumatoid arthritis patients? Best Pract Res 2001;15:125–37.

    OpenUrlCrossRef
16. 16.↵
    1. Quinn MA,
    2. Conaghan PG,
    3. Emery P

    . The therapeutic approach of early intervention for rheumatoid arthritis: what is the evidence? Rheumatology Oxford 2001;40:1211–20.

    OpenUrlAbstract/FREE Full Text
17. 17.
    1. Verstappen SM,
    2. Jacobs JW,
    3. Bijlsma JW,
    4. et al

    . Five-year followup of rheumatoid arthritis patients after early treatment with disease-modifying antirheumatic drugs versus treatment according to the pyramid approach in the first year. Arthritis Rheum 2003;48:1797–807.

    OpenUrlCrossRefPubMed
18. 18.↵
    1. Nell VP,
    2. Machold KP,
    3. Eberl G,
    4. Stamm TA,
    5. Uffmann M,
    6. Smolen JS

    . Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis. Rheumatology Oxford 2004;43:906–14.

    OpenUrlAbstract/FREE Full Text
19. 19.
    1. Keen HI,
    2. Emery P

    . How should we manage early rheumatoid arthritis? From imaging to intervention. Current Opin Rheumatol 2005;17:280–5.

    OpenUrlCrossRefPubMed
20. 20.↵
    1. Weinblatt ME

    . Rheumatoid arthritis: treat now, not later! Ann Intern Med 1996;124:773–4.

    OpenUrlPubMed
21. 21.↵
    1. Le Loet X,
    2. Berthelot JM,
    3. Cantagrel A,
    4. et al

    . Clinical practice decision tree for the choice of the first disease modifying antirheumatic drug for very early rheumatoid arthritis: a 2004 proposal of the French Society of Rheumatology. Ann Rheum Dis 2006;65:45–50.

    OpenUrlAbstract/FREE Full Text
22. 22.↵
    1. Combe B,
    2. Landewe R,
    3. Lukas C,
    4. et al

    . EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2007;66:34–45.

    OpenUrlAbstract/FREE Full Text
23. 23.
    1. Emery P,
    2. Breedveld FC,
    3. Dougados M,
    4. Kalden JR,
    5. Schiff MH,
    6. Smolen JS

    . Early referral recommendation for newly diagnosed rheumatoid arthritis: evidence based development of a clinical guide. Ann Rheum Dis 2002;61:290–7.

    OpenUrlAbstract/FREE Full Text
24. 24.↵
    1. Kennedy T,
    2. McCabe C,
    3. Struthers G,
    4. et al

    . BSR guidelines on standards of care for persons with rheumatoid arthritis. Rheumatology Oxford 2005;44:553–6.

    OpenUrlFREE Full Text
25. 25.↵
    1. Combe B

    . The French early arthritis registry. Clin Exp Rheumatol 2003;21:S123–8.

    OpenUrlPubMed
26. 26.↵
    1. Combe B,
    2. Benessiano J,
    3. Berenbaum F,
    4. et al

    . The ESPOIR cohort: A ten-year follow-up of early arthritis in France. Methodology and baseline characteristics of the 813 included patients. Joint Bone Spine 2007;74:440–5.

    OpenUrlCrossRefPubMed
27. 27.↵
    1. Arnett FC,
    2. Edworthy SM,
    3. Bloch DA,
    4. et al

    . The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315–24.

    OpenUrlCrossRefPubMed
28. 28.↵
    1. Denoeud L,
    2. Mazieres B,
    3. Payen-Champenois C,
    4. Ravaud P

    . First line treatment of knee osteoarthritis in outpatients in France: adherence to the EULAR 2000 recommendations and factors influencing adherence. Ann Rheum Dis 2005;64:70–4.

    OpenUrlAbstract/FREE Full Text
29. 29.
    1. Irwin ME,
    2. Bainey KR,
    3. Senaratne MP

    . Evaluation of the appropriateness of pacemaker mode selection in bradycardia pacing: how closely are the ACC/AHA guidelines followed? Pacing Clin Electrophysiol 2003;26:2301–7.

    OpenUrlCrossRefPubMed
30. 30.↵
    1. Perlis RH

    . Use of treatment guidelines in clinical decision making in bipolar disorder: a pilot survey of clinicians. Current Med Res Opin 2007;23:467–75.

    OpenUrlCrossRef
31. 31.↵
    1. Kvien TK,
    2. Heiberg,
    3. Lie E,
    4. et al

    . A Norwegian DMARD register: prescriptions of DMARDs and biological agents to patients with inflammatory rheumatic diseases. Clin Exp Rheumatol 2005;23:S188–94.

    OpenUrlPubMed
32. 32.
    1. Maravic M,
    2. Berge C,
    3. Daures JP,
    4. Boissier MC

    . Survey of practices regarding management of early rheumatoid arthritis by rheumatologists in France. Clin Exp Rheumatol 2004;22:319–27.

    OpenUrlPubMed
33. 33.
    1. Aletaha D,
    2. Smolen JS

    . The rheumatoid arthritis patient in the clinic: comparing more than 1,300 consecutive DMARD courses. Rheumatology Oxford 2002;41:1367–74.

    OpenUrlAbstract/FREE Full Text
34. 34.
    1. Jobanputra P,
    2. Wilson J,
    3. Douglas K,
    4. Burls A

    . A survey of British rheumatologists’ DMARD preferences for rheumatoid arthritis. Rheumatology Oxford 2004;43:206–10.

    OpenUrlAbstract/FREE Full Text
35. 35.
    1. Sokka T,
    2. Pincus T

    . Contemporary disease modifying antirheumatic drugs (DMARD) in patients with recent onset rheumatoid arthritis in a US private practice: methotrexate as the anchor drug in 90% and new DMARD in 30% of patients. J Rheumatol 2002;29:2521–4.

    OpenUrlAbstract/FREE Full Text
36. 36.↵
    1. Chan V,
    2. Tett SE

    . Changes in use of disease-modifying anti-rheumatic drugs in Australia over the period 1992–2004. Pharmacoepidemiol Drug Safety 2006;15:462–8.

    OpenUrlCrossRefPubMed
37. 37.↵
    1. van Dongen H,
    2. van Aken J,
    3. Lard LR,
    4. et al

    . Efficacy of methotrexate treatment in patients with probable rheumatoid arthritis: a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2007;56:1424–32.

    OpenUrlCrossRefPubMed
38. 38.↵
    1. Lard LR,
    2. Visser H,
    3. Speyer I,
    4. et al

    . Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: comparison of two cohorts who received different treatment strategies. Am J Med 2001;111:446–51.

    OpenUrlCrossRefPubMed
39. 39.↵
    1. van Aken J,
    2. Lard LR,
    3. le Cessie S,
    4. Hazes JM,
    5. Breedveld FC,
    6. Huizinga TW

    . Radiological outcome after four years of early versus delayed treatment strategy in patients with recent onset rheumatoid arthritis. Ann Rheum Dis 2004;63:274–9.

    OpenUrlAbstract/FREE Full Text
40. 40.↵
    1. Dixon WG,
    2. Symmons DP

    . Does early rheumatoid arthritis exist? Best Pract Res 2005;19:37–53.

    OpenUrlCrossRef
41. 41.↵
    1. Saraux A,
    2. Berthelot JM,
    3. Chales G,
    4. et al

    . Ability of the American College of Rheumatology 1987 criteria to predict rheumatoid arthritis in patients with early arthritis and classification of these patients two years later. Arthritis Rheum 2001;44:2485–91.

    OpenUrlCrossRefPubMed
42. 42.↵
    1. Huizinga TW,
    2. Machold KP,
    3. Breedveld FC,
    4. Lipsky PE,
    5. Smolen JS

    . Criteria for early rheumatoid arthritis: from Bayes’ law revisited to new thoughts on pathogenesis. Arthritis Rheum 2002;46:1155–9.

    OpenUrlCrossRefPubMed
43. 43.↵
    1. Headrick LA,
    2. Speroff T,
    3. Pelecanos HI,
    4. Cebul RD

    . Efforts to improve compliance with the National Cholesterol Education Program guidelines. Results of a randomized controlled trial. Arch Intern Med 1992;152:2490–6.

    OpenUrlCrossRefPubMed